Clinical Trial

A Study of Neoadjuvant TCHpy（Pyrotinib ，Trastuzumab，Carboplatin and Paclitaxel）for ER+/HER2+ Breast Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 21, 2023 (before its estimated May 11, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is a multicenter, single-arm, prospective, open clinical study to evaluate the efficacy and safety of pyrotinib in combination with trastuzumab, albumin paclitaxel, and carboplatin in neoadjuvant therapy for ER+/HER2+ early or locally advanced breast cancer.
Trial Details
NCT Number NCT06000917
Lead Sponsor Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Conditions Breast Cancer, Neoadjuvant
Enrollment 62 participants
Start Date 2023-05-11
Primary Completion 2025-05-11 (estimated)
Study Completion 2028-05-11 (estimated)
Updated on ClinicalTrials.gov 2023-08-21